Cereno Scientific strengthens patent protection for CS1 with first granted patent in the third patent family
Cereno Scientific (XSAT: CRNO B) today announced that intellectual property rights (IPR) for drug candidate CS1’s third patent family has been granted in Russia. This is the first patent grant in the third patent family, adding to Cereno’s extensive patent protection across nearly all global key markets.
“It is great to see our continuous work in securing IPR for our assets paying off with further strengthening of the patent protection for CS1 in the Russian market.” says Sten R. Sörensen, CEO at Cereno Scientific.
Jonas Faijerson Säljö, Chief Intellectual Property Officer at Cereno Scientific, adds “Having a comprehensive and strong IPR portfolio is key to protecting the significant investment involved in developing and launching new drugs. We are therefore pleased to expand our extensive patent protection to the third patent family for CS1.”
The patent granted in Russia, part of Cereno’s third patent family associated with drug candidate CS1, is titled “Delayed release pharmaceutical formulations comprising valproic acid and uses thereof”. It has been given patent number RU2760304 and will be valid through 2037, with the possibility of a patent extension of additional five years maximum.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.